Emerging clinical evidence supports these findings, with observational studies indicating reduced alcohol-related events in patients treated with GLP1-RAs for T2DM or obesity [6]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.